Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou(Tongji University), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Yiping Zhang(National Health and Family Planning Commission), Jiuwei Cui(Jilin University), Lizhu Lin(Guangzhou University of Chinese Medicine), Yi Hu(Union Hospital), Zhehai Wang(Shandong Tumor Hospital), Jianying Zhou(First Affiliated Hospital Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), Wei Shi(Jiangsu Hengrui Medicine (China)), Yongqian Shu(Jiangsu Province Hospital), Xiaorong Dong(The University of Melbourne), Jian Fang(Peking University), Wei Zhang(Nanchang University), Qun Chen(Unknown), Yongsheng Wang(Guangzhou University of Chinese Medicine), Jianhua Chen(Hunan Cancer Hospital), Qiming Wang(Hunan Cancer Hospital), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Zhiyong He(Albert Einstein College of Medicine), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Xiaoyan Lin(Fujian Medical University), Jifeng Feng(Zhejiang Cancer Hospital), Kangsheng Gu(Anhui Medical University), Jianhua Shi(Linyi People's Hospital), Yunchao Huang(Kunming Medical University), Tao Zhang(Jiangsu Hengrui Medicine (China)), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Gongyan Chen(Harbin Medical University), Jianhua Chang(Shanghai Medical College of Fudan University), Yueyin Pan(University of Science and Technology of China), Liping Wang(Shihezi University), Fengying Wu(Shanghai Sixth People's Hospital)
The Lancet Respiratory Medicine
December 18, 2020
10.1016/s2213-2600(20)30365-9
Cited by 504

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k